Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (ACIU) is a Swiss clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases like Alzheimer's. This page provides investors and researchers with centralized access to official news, financial disclosures, and scientific developments directly from the company.
Key resources include earnings reports, clinical trial updates, strategic collaborations, and regulatory milestones. Stay informed on ACIU's progress in developing diagnostic tools and therapies targeting protein misfolding pathologies through its proprietary platforms.
Content spans pipeline advancements, peer-reviewed research highlights, and material business events. Bookmark this page to efficiently track ACIU's contributions to neuroscience innovation and make data-driven decisions based on verified company communications.
AC Immune SA (NASDAQ: ACIU) announced significant clinical advancements and financial updates. The company has delivered three clinical readouts in 2022 and aims for four more by year-end. The first patient has been dosed in the Phase 1b/2 trial of its anti-Abeta vaccine ACI-24.060 targeting Alzheimer's and Down syndrome. Financially, AC Immune holds CHF 154.1 million, ensuring operations through Q1 2024. However, a net loss of CHF 19.6 million was reported for Q2 2022, slightly higher than the previous year's loss.
AC Immune SA (NASDAQ: ACIU) has announced its participation in the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022, in San Diego. The company will present 10 findings, including new Phase 2 results for the Tau PET tracer PI-2620 and an innovative clinical trial design for ACI-24.060 aimed at Alzheimer's and Down syndrome patients. CEO Andrea Pfeifer emphasized the significance of these results in shifting treatment paradigms for neurodegenerative diseases, highlighting the collaboration with partners like Genentech.
AC Immune SA (NASDAQ: ACIU) held its Annual General Meeting in June 2022, where shareholders re-elected the Board of Directors. Douglas Williams continues as Chairman. The company reported progress in its pipeline, including interim Phase 1b/2a data for the anti-pTau vaccine ACI-35.030 and clinical proof-of-concept for an alpha-synuclein PET tracer. They remain on track for four additional clinical data readouts in 2022 and have sufficient cash for operations into 2024.
AC Immune SA (NASDAQ: ACIU) announced results from its Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial. The investigational drug, crenezumab, did not statistically significantly slow cognitive decline in patients with a specific genetic mutation linked to early-onset Alzheimer’s. Although numerical advantages over placebo were noted, they lack statistical significance. The trial, involving 252 participants, reported no new safety issues. Initial data will be shared at the Alzheimer's Association International Conference on August 2, 2022.
AC Immune announced participation in the 2022 Jefferies Healthcare Conference from June 8-10, 2022, in New York. CEO Andrea Pfeifer will discuss the company's progress in neurodegenerative disease treatments during a fireside chat on June 9 at 8:00 am EDT. The company aims to shift the treatment paradigm towards early diagnosis and disease prevention. Key milestones include the reporting of Phase 2 results for crenezumab in an Alzheimer's prevention trial, expected soon. AC Immune is focused on advancing precision medicine through its innovative therapeutic and diagnostic pipeline.
AC Immune (NASDAQ: ACIU) announced that CEO Dr. Andrea Pfeifer will receive the Aenne Burda Award for Creative Leadership during the DLD Conference in Munich, May 20-22, 2022. This award recognizes her pioneering work in neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Under her leadership since 2003, AC Immune has developed a promising pipeline of diagnostics and treatments, positioning the company as a leader in precision medicine. The award highlights the urgency of addressing global challenges posed by these diseases.
AC Immune SA (NASDAQ: ACIU) has published findings in JAMA Neurology demonstrating the safety and immunogenicity of its ACI-24 anti-Abeta vaccine in individuals with Down syndrome (DS). This Phase 1b trial showed a positive immune response without serious adverse effects, indicating the vaccine's potential for future Alzheimer’s disease interventions. An optimized formulation is set to enter further clinical testing this year, reinforcing AC Immune's commitment to addressing neurodegenerative diseases.
AC Immune, a clinical-stage biopharmaceutical company, reported Q1 2022 results highlighting key advancements in neurodegenerative disease treatments. They announced favorable interim data from the ACI-35.030 anti-pTau vaccine, showcasing strong immunogenicity and safety. Additionally, the ACI-12589 PET tracer provided first images of alpha-synuclein in human brains, critical for diagnosing MSA. With a solid cash position of CHF 173.8 million, the company remains funded through at least Q1 2024, expecting five more clinical readouts by year's end to boost value creation.
AC Immune SA (NASDAQ: ACIU) announced its participation in the B.Riley Annual Neuro & Ophthalmology Virtual Investor Conference on April 27-28, 2022. CEO Prof. Andrea Pfeifer will host a Fireside chat on April 28 at 11:30 am EDT, discussing the company's development pipeline for neurodegenerative diseases and upcoming clinical milestones. Having achieved two milestones in Q1, AC Immune will present five more data readouts this year, highlighting its precision medicine approach. The webcast will be available on the company's website.
AC Immune SA (NASDAQ: ACIU) announces significant management changes, appointing Howard Donovan as Chief HR Officer and promoting Chris Roberts to Interim CFO, due to Joerg Hornstein's departure. Donovan brings extensive HR experience from the World Economic Forum, while Roberts has a strong finance background, essential for AC Immune's financial operations. Julian Snow is also promoted to Vice President, U.S. Finance & Corporate Development. The changes aim to strengthen the company's internal functions as it continues to develop precision medicine for neurodegenerative diseases.
FAQ
What is the current stock price of AC Immune (ACIU)?
What is the market cap of AC Immune (ACIU)?
